相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cysteinyl-tRNA Deacylation Can Be Uncoupled from Protein Synthesis
Alexandre David et al.
PLOS ONE (2012)
The Proteasome in Terminal Plasma Cell Differentiation
Simone Cenci
SEMINARS IN HEMATOLOGY (2012)
Proteostenosis and plasma cell pathophysiology
Simone Cenci et al.
CURRENT OPINION IN CELL BIOLOGY (2011)
RNA Binding Targets Aminoacyl-tRNA Synthetases to Translating Ribosomes
Alexandre David et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Amyloidosis: Pathogenesis and New Therapeutic Options
Giampaolo Merlini et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Early Marginal Zone B Cell-Initiated T-Independent Type 2 Response Resists the Proteasome Inhibitor Bortezomib
Veronika R. Lang et al.
JOURNAL OF IMMUNOLOGY (2010)
Proteasomes in immune cells: more than peptide producers?
Marcus Groettrup et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production
D. K. Perry et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Protein Homeostasis and Aging: Taking Care of Proteins From the Cradle to the Grave
Richard I. Morimoto et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2009)
Innate immune and chemically triggered oxidative stress modifies translational fidelity
Nir Netzer et al.
NATURE (2009)
Dampening Ab responses using proteasome inhibitors following in vivo B cell activation
Paolo Cascio et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging
Richard I. Morimoto
GENES & DEVELOPMENT (2008)
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
Kirsten Neubert et al.
NATURE MEDICINE (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells
Francesca Romana Santoni de Sio et al.
STEM CELLS (2008)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Enhanced expression of interferon-γ-induced antigen-processing machinery components in a spontaneously occurring cancer
Fulvia Cerruti et al.
NEOPLASIA (2007)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
Managing and exploiting stress in the antibody factory
Simone Cenci et al.
FEBS LETTERS (2007)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction
Francesca Romana Santoni de Sio et al.
BLOOD (2006)
Progressively impaired proteasomal capacity during terminal plasma cell differentiation
S Cenci et al.
EMBO JOURNAL (2006)
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells
ST Nawrocki et al.
CANCER RESEARCH (2005)
Quantifying the contribution of defective ribosomal products to antigen production:: A model-based computational analysis
S Bulik et al.
JOURNAL OF IMMUNOLOGY (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Proteasome inhibitor therapy in multiple myeloma
D Chauhan et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation
EJ Bennett et al.
MOLECULAR CELL (2005)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Early events in spontaneous neutrophil apoptosis
D Scheel-Toellner et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2004)
Protein degradation and protection against misfolded or damaged proteins
AL Goldberg
NATURE (2003)
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim
R Ley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Quantitating protein synthesis, degradation, and endogenous antigen processing
MF Princiotta et al.
IMMUNITY (2003)
Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion
E van Anken et al.
IMMUNITY (2003)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
T Hideshima et al.
NATURE REVIEWS CANCER (2002)
Role of the CC Chemokine receptor 9/TECK interaction in apoptosis
BS Youn et al.
APOPTOSIS (2002)
The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction
MH Glickman et al.
PHYSIOLOGICAL REVIEWS (2002)
Proteasome inhibitors: from research tools to drug candidates
AF Kisselev et al.
CHEMISTRY & BIOLOGY (2001)
Impairment of the ubiquitin-proteasome system by protein aggregation
NF Bence et al.
SCIENCE (2001)
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
U Schubert et al.
NATURE (2000)
Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression
BY Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells
NP Dantuma et al.
NATURE BIOTECHNOLOGY (2000)
分享论文
